Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$80.68 - $121.90
Previous CloseN/A
Volume168.58K
Average Volume (3M)932.32K
Market Cap
$5.67B
Enterprise Value$5.66B
Total Cash (Recent Filing)$47.24M
Total Debt (Recent Filing)$9.04M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 01, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding63,906,010
10 Day Avg. Volume979,176
30 Day Avg. Volume932,324
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.14
Price to Cash Flow (P/CF)-48.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.57
Enterprise Value/Ebitda-34.49
Forecast
1Y Price Target
$130.00Price Target Upside46.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityBPMC is seen as an attractive stock due to its overall beat-and-raise growth profile and limited competition in its commercial profile, with significant revenue potential.
Product GrowthAyvakit has demonstrated steady growth since its first-in-disease ISM approval, driven in part by new patient starts and a broadening/deepening prescriber base.
Product PotentialMost investors are excited about -808 for non-urticaria indications, especially MCAS and allergic asthma.
Bears Say
Product UncertaintyThe fate of BLU-808 (the urticaria product) seems uncertain, as it would need to become a viable, niche product among established medications.
Revenue ConcernsThe company's softer tone on Q1 revenue spooked investors, causing a small weakness in the stock.
Safety ConcernsSafety remains a concern with bezuclastinib, especially the liver signal.
---
Ownership Overview
1.56% Insiders
42.51% Mutual Funds
26.50% Other Institutional Investors
12.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $80.67 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Blueprint Medicines’s market cap is $5.67B.
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is May 01, 2025 which is in 30 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Feb 13, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.086.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -0.51.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,906,010 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went down -8.082%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Currently, no hedge funds are holding shares in BPMC
---
Blueprint Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.00 (46.88% Upside)
$130.00 (46.88% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 84.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.47%
12-Months-Change
Fundamentals
Return on Equity
-31.26%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
---
BPMC Company Deck
---
BPMC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong revenue growth and market expansion for AYVAKIT, successful international progress, promising development of BLU-808, and financial discipline. However, some challenges in Q1 2025 and a heavy reliance on the U.S. market were noted.Read More>---
BPMC Stock 12 Month Forecast
Average Price Target
$130.00
▲(46.88% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+10.87%
reiterated a buy rating 2 months ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +10.87% per trade.
---